Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

metastatic colorectal cancer

  • You have access
    A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202)
    AYA KATO, NORIKATSU MIYOSHI, TORU OHTSURU, DAISUKE SAKAI, JUNICHI HASEGAWA, KEN NAKATA, MITSUNOBU IMASATO, TAKESHI KATO, MASAKAZU IKENAGA, TOSHIHIRO KUDO, MITSUYOSHI TEI, YOSHINORI KAGAWA, MAMORU UEMURA, HIDEKAZU TAKAHASHI, TAROH SATOH, MASAKI MORI, TSUNEKAZU MIZUSHIMA, HIROFUMI YAMAMOTO, KOHEI MURATA, YUICHIRO DOKI and HIDETOSHI EGUCHI
    Anticancer Research April 2022, 42 (4) 1859-1865; DOI: https://doi.org/10.21873/anticanres.15662
  • You have access
    The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting
    MASATSUNE SHIBUTANI, WANG EN, YUKI OKAZAKI, SHINICHIRO KASHIWAGI, TATSUNARI FUKUOKA, YASUHITO ISEKI, KOSEI HIRAKAWA and MASAICHI OHIRA
    Anticancer Research December 2021, 41 (12) 6211-6216; DOI: https://doi.org/10.21873/anticanres.15440
  • You have access
    Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
    TARO SATO, HIROKI OSUMI, EIJI SHINOZAKI, AKIRA OOKI, KEITARO SHIMOZAKI, DAISAKU KAMIIMABEPPU, IZUMA NAKAYAMA, TAKERU WAKATSUKI, MARIKO OGURA, DAISUKE TAKAHARI, KEISHO CHIN and KENSEI YAMAGUCHI
    Anticancer Research August 2021, 41 (8) 3905-3915; DOI: https://doi.org/10.21873/anticanres.15186
  • You have access
    Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
    MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA
    Anticancer Research June 2021, 41 (6) 3091-3097; DOI: https://doi.org/10.21873/anticanres.15093
  • You have access
    Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
    TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA
    Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988
  • You have access
    Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
    YUSUKE NIISATO, TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, TOSHIKI MASUISHI, ATSUO TAKASHIMA, YOSUKE KUMEKAWA, TAKESHI KAJIWARA, KENTARO YAMAZAKI, TAITO ESAKI, AKITAKA MAKIYAMA, TADAMICHI DENDA, YUKIMASA HATACHI, TAKESHI SUTO, NAOTOSHI SUGIMOTO and YASUHIRO SHIMADA
    Anticancer Research April 2021, 41 (4) 2203-2207; DOI: https://doi.org/10.21873/anticanres.14996
  • You have access
    Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
    MARIOS PAPADIMITRIOU and CHRISTOS A. PAPADIMITRIOU
    Anticancer Research February 2021, 41 (2) 567-582; DOI: https://doi.org/10.21873/anticanres.14809
  • You have access
    Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
    MICHIO KIMURA, EISEKI USAMI and TOMOAKI YOSHIMURA
    Anticancer Research December 2020, 40 (12) 7135-7140; DOI: https://doi.org/10.21873/anticanres.14743
  • You have access
    Association of C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer
    ALLAN RAMOS-ESQUIVEL, RICARDO CHINCHILLA and MARTA VALLE
    Anticancer Research August 2020, 40 (8) 4263-4270; DOI: https://doi.org/10.21873/anticanres.14428
  • You have access
    Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis
    AKIHISA MATSUDA, TAKESHI YAMADA, SUPASCHIN JAMJITTRONG, SEIICHI SHINJI, RYO OHTA, HIROMICHI SONODA, TUNYAPORN KAMONVARAPITAK, KUMIKO SEKIGUCHI, MASAO MIYASHITA, HIDEYUKI SUZUKI and HIROSHI YOSHIDA
    Anticancer Research June 2020, 40 (6) 3469-3476; DOI: https://doi.org/10.21873/anticanres.14333

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire